User profiles for Christopher J Destache

Christopher Destache

Verified email at creighton.edu
Cited by 4750

Nanotechnology: a focus on nanoparticles as a drug delivery system

…, B Rabinow, HE Gendelman, CJ Destache - Journal of Neuroimmune …, 2006 - Springer
This review will provide an in-depth discussion on the previous development of nanoparticle-based
drug delivery systems (DDS) and discuss original research data that includes the …

Therapeutic immunization protects dopaminergic neurons in a mouse model of Parkinson's disease

EJ Benner, RL Mosley, CJ Destache… - Proceedings of the …, 2004 - National Acad Sciences
Degeneration of the nigrostriatal dopaminergic pathway, the hallmark of Parkinson's disease,
can be recapitulated in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-intoxicated …

Development of a macrophage-based nanoparticle platform for antiretroviral drug delivery

H Dou, CJ Destache, JR Morehead, RL Mosley… - Blood, 2006 - ashpublications.org
Complex dosing regimens, costs, side effects, biodistribution limitations, and variable drug
pharmacokinetic patterns have affected the long-term efficacy of antiretroviral medicines. To …

Macrophage delivery of nanoformulated antiretroviral drug to the brain in a murine model of neuroAIDS

…, CJ Destache, M Chaubal, J Werling, J Kipp… - The Journal of …, 2009 - journals.aai.org
Antiretroviral therapy (ART) shows variable blood-brain barrier penetration. This may affect
the development of neurological complications of HIV infection. In attempts to attenuate viral …

Early versus late surgical intervention or medical management for infective endocarditis: a systematic review and meta-analysis

…, RM Suri, G Mansour, CJ Destache, J Baskaran… - Heart, 2016 - heart.bmj.com
Objective Infective endocarditis is associated with high morbidity and mortality and optimal
timing for surgical intervention is unclear. We performed a systematic review and meta-…

[HTML][HTML] Combination antiretroviral drugs in PLGA nanoparticle for HIV-1

CJ Destache, T Belgum, K Christensen, A Shibata… - BMC infectious …, 2009 - Springer
Background Combination antiretroviral (AR) therapy continues to be the mainstay for HIV
treatment. However, antiretroviral drug nonadherence can lead to the development of …

Development and evaluation of a thermosensitive vaginal gel containing raltegravir+ efavirenz loaded nanoparticles for HIV prophylaxis

…, B Sanford, K La Bruzzo, M Belshan, CJ Destache - Antiviral research, 2012 - Elsevier
The objective of this investigation was to develop a thermosensitive vaginal gel containing
raltegravir+efavirenz loaded PLGA nanoparticles (RAL+EFV–NPs) for pre-exposure …

Individualized pharmacokinetic monitoring results in less aminoglycoside‐associated nephrotoxicity and fewer associated costs

…, AN Nafziger, CJ Destache… - … : The Journal of …, 2001 - Wiley Online Library
Study Objective. To examine the impact of individualized pharmacokinetic monitoring (IPM)
on the development of aminoglycoside‐associated nephrotoxicity (AAN). Design. …

Nucleotide reverse transcriptase inhibitors: a thorough review, present status and future perspective as HIV therapeutics

…, S Mandal, PK Prathipati, CJ Destache - Current HIV …, 2017 - ingentaconnect.com
Background: Human immunodeficiency virus type-1 (HIV-1) infection leads to acquired
immunodeficiency syndrome (AIDS), a severe viral infection that has claimed approximately …

A review of nanotechnological approaches for the prophylaxis of HIV/AIDS

AA Date, CJ Destache - Biomaterials, 2013 - Elsevier
Successful treatment and control of HIV/AIDS is one of the biggest challenges of 21st century.
More than 33 million individuals are infected with HIV worldwide and more than 2 million …